News Merck's rare tumour drug Pimjetmi claims FDA approval Merck's Pimjetmi has been cleared in the US for tenosynovial giant cell tumour, adding a third FDA-approved treatment for the rare disorder.
News Merck charts course out of CDMO business with Lonza sale Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
News Merck buys Silence and its siRNA pipeline for $1.3bn Merck KGaA is slated to acquire UK-based Silence Therapeutics in a $1.3bn deal that would give it a late-stage drug for polycythemia vera.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
News Merck buys life sciences firm Bio-Techne in $11.3bn deal Merck KGaA is poised to increase the size of its life sciences business with an $11.3 billion deal to acquire rival Bio-techne.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.